Stifel analyst Annabel Samimy maintain Horizon Therapeutics (HZNP) as a Select List and Top Pick, citing the visible growth drivers of Krystexxa and teprotumumab as well as the company's "proven execution prowess." She also called Evolus (EOLS) an "underappreciated Select List Pick" given its "excellent execution" in the cash pay neurotoxin market. Among development-stage companies, Samimy selected Cara Therapeutics (CARA) as her Top Pick, noting that it will have three clinical trial read-outs in distinct pruritus indications this year and has lost nearly all value related to Oral Korsuva despite the drug's established clinical activity. She has Buy rating and $45 price target on Horizon, Buy rating and $33 price target on Evolus and Buy rating and $33 price target on Cara shares.

The company states: "Evolus announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau(R) (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The "extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau(R) Extra-Strength 40U and two active controls, BOTOX(R) 20U and Jeuveau(R) 20U. Efficacy results demonstrated 26 weeks, or 6 months duration across the multiple metrics presented, including the time it took for patients to return to their baseline GLS score after their treatment, the duration of effect for a patient with at least a one-point GLS improvement, and the time it took a patient to return to their baseline using the Global Aesthetic Improvement Scale. The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified."